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In a monocentric and prospective study involving 96 consecutive patients (stable angina:
28; unstable angina: 30 and recent myocardial infarction: 38) referred to PCI revasculari-
sation, we determined the concentrations of serum MMP 2-9 and TIMP 1-2. Each patient
was treated with one or more non-drug eluting stent, with or without balloon-predilatation.
Blood was sampled from aorta before and immediately post-PCI and from venous access
24 hours later (J1). MMPs plasma concentrations were measured by enzyme-linked
immunoabsorbent assay. Follow-up (15.4 ± 3.2 months) documented the occurrence of
reintervention, myocardial infarction (MI) and death. Value are expressed as mean ±
SEM.
Results:
About MMP2 plasma level, there was a trend to higher values after PCI followed by a
decrease at J1. Those variations did not reached the significant level. By contrast,
MMP9, TIMP 2-9 were significantly lower after PCI then increased significantly at J1, for
the whole population and the3 different subgroup of clinical status. Despite non signifi-
cant variation for the whole population and subgroups, post-PCI MMP2 plasma level cor-
related with reintervention (p: 0.0003). Furthermore, a positive variation of MMP2
between pre and post-PCI (p: 0.0003) as well as a negative variation of MMP 2 between
post-PCI and J1 (p: 0.0009) correlated both with reintervention.
Conclusions:
Variations of MMPs and inhibitors immediately after PCI can be documented through
conventional vessel access. MMP2 kinetic after stent implantation allows interesting
information regarding the risk of reintervention.
1043-48 Impact of Cerebrovascular and Peripheral Arterial 
Disease on Outcomes After Percutaneous Coronary 
Interventions
Eugenia Nikolsky, Roxana Mehran, George D. Dangas, Gary S. Mintz, Zoran Lasic, Tudor 
Vagaonescu, Ramona Pop, Alexandra J. Lansky, Issam Moussa, Lynn Glasser, Sharif 
Ibrahim, Iyer Sriram, Martin B. Leon, The Cardiovascular Research Foundation and the 
Lenox Hill Heart and Vascular Institute, New York, NY
Background. Cerebrovascular and peripheral arterial diseases frequently coexist in pts
with coronary artery disease (CAD).Whether the presence of cerebrovascular disease
(CVD) alone or in combination with peripheral arterial disease (PAD) influences the out-
comes of percutaneous coronary intervention (PCI) is not known. We compared the
impact of symptomatic CVD and/or PAD on the prognosis of pts undergoing PCI. Meth-
ods and Results. Of 10,428 pts, symptomatic CVD, PAD, or both were identified in 743
(7.1%), 1,541 (14.8%) and 424 (4.1%) pts, respectively. Compared to the remaining
7,720 pts without these conditions (controls), pts with CVD, PAD, or both were older,
more frequently female, and had lower ejection fraction. Pts with CVD, PAD, or both had
higher than controls rates of in-hospital mortality (2.8%, 2.0%, and 2.4%, respectively, vs
0.9%, P<0.0001), stroke (0.8%, 0.5%, and 1.2% vs 0.2%, P=0.0015), and limb ischemia
(1.6%, 3.0%, and 3.1% vs 0.6%, P<0.0001). One-year outcomes were significantly worse
in pts with CVD, PAD, or both than in controls (Table). By multivariate analysis, CVD was
an independent predictor of in-hospital mortality (odds ratio=2.29, P=0.0031). One-year
mortality was predicted by either CVD (odds ratio=1.44, P=0.02) or PAD (odds
ratio=1.76, P<0.0001); but the two were not additive. Conclusions: Symptomatic CVD
and/or PAD are associated with adverse in-hospital and 1-year outcomes and indepen-
dently predict in-hospital and/or 1-year mortality.
1043-49 Current Percutaneous Transluminal Coronary 
Angioplasty Practice and Clinical Outcomes in the 
Netherlands: The Real World
Pascalle S. Monraats, Willem R.P Agema, Aeilko H. Zwinderman, Robbert J. de Winter, 
Rene A. Tio, Pieter A.F.M Doevendans, Harry J.G.M Crijns, Moniek P.M de Maat, Douwe 
E. Atsma, Arnoud van der Laarse, Ernst E. van der Wall, J.Wouter Jukema, Leiden 
University Medical Center, Leiden, The Netherlands
Background: Percutaneous transluminal coronary angioplasty (PTCA) is limited by the
recurrence of luminal stenosis. This study evaluated the incidence and risk factors of clin-
ical restenosis in an unselected patient population with contemporary intervention tech-
niques in the pre-Drug Eluting Stent (DES) era.
Methods: The GEnetic DEterminants of Restenosis (GENDER) project was a multi-
center prospective cohort study, which included 3,146 patients after successful PTCA.
Patients with acute myocardial infarction (MI) were excluded.
Results: A total of 3,146 patients (age 62.1±10.7 yrs) were followed for 10±3 months. Of
the patients 2,250 (71.5%) were male, 459 (14.6%) had diabetes and 1,459 (46.4%) had
multivessel disease. The majority was treated for stable angina. Stenting was performed
in 2,340 (74.4%) patients and IIb/IIIa inhibitors were used in 820 (26.1%) patients. Target
vessel revascularization after the first month by either CABG or PTCA was necessary in
304 patients (9.7%). Thirty-three (1.1%) died of cardiac disease and 22 (0.7%) suffered
from MI attributable to the originally treated vessel. Overall a need for revascularization,
cardiac death or MI occurred in 346 patients (11.0%). After correction for all baseline
characteristics in a multivariate analysis; diabetes, hypertension, peripheral vessel dis-
ease, multivessel disease and treatment of type C lesions prevailed as independent risk
factors for clinical restenosis. After dividing the patients into subgroups depending upon
the number of risk factors present in these patients, we constructed six subgroups. Group
one had zero or one risk factor (n=700) and a clinical restenosis rate of 7.6%, whereas
group three, with four or five risk factors (n=386) had a rate of 17.3% after one year fol-
low-up.
Conclusion: In this unselected series of patients clinical restenosis occurred in only
11.0%. Proper selection of patients that benefit from new devices is warranted, since the
vast majority is well treated with standard techniques. Although patients with more clini-
cal risk factors show a higher restenosis rate, it remains difficult to predict events.
Genetic determinants may have additional value for stratifying patients at risk.
1043-50 The Extent of Coronary Atherosclerosis Determined by 
Angioscopy Is a Risk Factor of Restenosis
Yasunori Ueda, Isamu Mizote, Tomohito Ohtani, Masaya Usami, Takashi Oka, Astushi 
Hirayama, Kazuhisa Kodama, Osaka Police Hospital, Osaka, Japan
Background: Although the development in the techniques and devices for PCI has
reduced the restenosis rate, restenosis has not been completely prevented and its risk
factors have not been thoroughly clarified. Progression of atherosclerosis is known to
increase the inflammation and thrombus formation, which may promote restenosis.
Therefore, we tested if angioscopically determined extent of atherosclerosis could be a
risk factor of restenosis.
Methods: Among 1050 patients of ischemic heart disease who received PCI, angioscopic
evaluation of coronary atherosclerosis was performed in 263 patients. Target vessel was
observed by angioscopy and the color of plaques was graded as 0 (white), 1 (slight yel-
low), 2 (yellow), or 3 (intensive yellow). The extent of atherosclerosis was assessed by
the number of yellow plaques (N), maximum (MC) and sum (SC) of color grade of
observed plaques. The rate of target vessel revascularization (TVR) was used as the
marker of restenosis.
Results: TVR of all 1050 patients was 19%, and of all 263 patients who received angio-
scopic examination was 16%. TVR increased according to the increase in N (N3, 29%),
MC (MC=1, 10%; MC=2, 16%; MC=3, 23%), and SC (SC<3, 16%; SC>3, 23%; SC>5,
25%; SC>7, 27%; SC>9, 29%). Repeat TVR also increased according to the increase in
N (N=0/1, 0%; N=2, 9%; N>3, 21%), MC (MC=0/1, 0%; MC=2, 11%; MC=3, 29%), and
SC (SC=0/1, 0%; SC=2/3, 6%; SC>4, 24%).
Conclusions: Angioscopically determined extent of coronary atherosclerosis according to
the number of yellow plaques and the yellow color intensity of plaques is a risk factor of
restenosis.
1043-63 Elevated Peak Rather Than Admission White Blood Cell 
Count Is Associated With Adverse Cardiovascular 
Outcome in Patients Undergoing Percutaneous 
Coronary Intervention for Acute Myocardial Infarction
Ahmed S. Ahmed, Mohammed Murtaza, Almutaz Kartoumah, Christopher Bartalos, 
Ambareesh Bajpai, Jennifer Jean Marcellus, Tarek Kteleh, Rasha Mohamed, Daniel 
Noonan, James Boyd Sterner, Timothy Catchings, Richard Webel, Greg C. Flaker, 
University of Missouri-Columbia, Columbia, MO
Background:
The role of inflammation in acute coronary syndrome is well established. Recent studies
suggest that elevated admission white blood cell count (WBC) is associated with adverse
outcomes in patients undergoing PCI for acute myocardial infarction (AMI).
Hypothesis:
Peak rather than admission WBC in patients undergoing PCI for AMI is a better marker of
the magnitude of inflammation and thus more accurately predicts adverse long term out-
come.
Methods:
Prospectively collected data on consecutive patients undergoing PCI for AMI was
obtained from the American College of Cardiology-National Cardiovascular Data Regis-
try. Patients were divided into 5 strata based on WBC. Three years follow up data for
major adverse cardiac events was analyzed.
Results:
There were 496 patients including 260/496 (52.42%) patients with ST elevation AMI and
236/496 (47.58%) patients with non ST elevation AMI. The peak WBC ranged from 3.8 to
44.9 X109/L. The admission WBC ranged from 2.4 to 31.6 X109/L. Baseline characteris-
tics including age, gender and cardiac risk factors were not significantly different among
groups. High peak WBC was associated with higher mortality (p <0.0001) while elevated
admission WBC failed to show statistically significant relationship to outcome.
Conclusion:
WBC count, a readily available inflammatory marker is useful in stratifying low Vs high-
risk patients with AMI undergoing PCI.
Elevated peak WBC count could select patients for more aggressive therapeutic strate-
gies. 
One-Year Outcomes
Endpoint, % (+)CVD
(-)PAD
N=743
(-)CVD
(+)PAD
N=1541
(+)CVD
(+)PAD
N=424
(-)CVD
(-)PAD
N=7720
P-value*
Death 9.9 12.6 16.7 4.7 <0.0001
Q-wave MI 1.5 1.0 2.3 1.2 0.19
Non-Q wave MI 6.6 6.3 9.4 5.2 0.004
TVR 21.5 25.0 23.1 21.2 0.02
*Chi-square statistics
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1043-64 Adverse Outcomes in Women Undergoing 
Percutaneous Coronary Intervention
Laxmi S. Mehta, James A. Goldstein, Stephen J. Mattichak, Renato G. Ramos, Judith 
Boura, Randy Miller, Cindy L. Grines, William W. O'Neill, William Beaumont Hospital, 
Royal Oak, MI
Background: Although cardiovascular disease is the most common cause of death in
women in the United States, females are generally underrepresented in clinical trials.
This study was designed to investigate whether there are differences in baseline risk fac-
tors between genders that influence outcomes after percutaneous coronary intervention
(PCI).
Methods: We analyzed 20,870 patients from the William Beaumont Hospital Interven-
tional Database. We compared baseline characteristics and in-hospital outcomes
between women (n=6745, 32%) and men (n=14125, 68%).
Results: Women were older (68 + 11 vs 63 + 11, p<0.0001) and had a higher prevalence
of risk factors including diabetes (32% vs 25%, p<0.0001), hypertension (71% vs 61%,
p<0.0001), though not hypercholesterolemia (62.7% vs 64.5%, p=0.012). Women also
had a higher incidence of congestive heart failure (18% vs 11%, p<0.0001), chronic renal
failure (4.3% vs 3.5%, p=0.0076), stroke (11% vs 7.5%, p<0.0001) and peripheral vascu-
lar disease (17% vs 14%, p<0.0001). Importantly women were less likely to have a prior
history of angioplasty (35% vs 38%, p<0.0001) and bypass surgery (16% vs 22%,
p<0.0001). Women were more likely to be treated with balloon angioplasty alone (40% vs
36%, p<0.0001) whereas men were more likely to undergo stenting (53% vs 56%,
p=0.0043). Women suffered more in-hospital post-procedural complications including
pulmonary edema (0.4% vs 0.2%, p=0.02), renal failure (2.1% vs 1.6%, p=0.0073), reoc-
clusion (0.5% vs 0.2%, p=0.0012), retroperitoneal bleed (0.6% vs 0.1%, p<0.0001),
strokes (0.6% vs 0.3%, p=0.012), and death (2.6% vs 1.3%, p<0.0001).
Conclusions: Women undergoing PCI have more high-risk cardiovascular characteris-
tics and have a higher incidence of in-hospital adverse outcomes compared to men.
1043-65 Simple Risk Score Predicts Myocardial Infarction and 
Cardiovascular Death at 30 Days After Percutaneous 
Coronary Intervention: An Analysis of the REPLACE-2 
and TARGET Data
David G. Burger, Gang Jia, Neal S. Kleiman, Baylor College of Medicine, Houston, TX
Background:A reliable way to predict the risk of death or myocardial infarction (MI) after
Percutaneous Coronary Intervention (PCI) in the era of glycoprotein IIb/IIIa inhibitors and
stent use has been elusive. Using a multivariable logistic regression model in a large PCI
trial database, we developed and tested a cumulative risk score to predict likelihood of MI
or Cardiovascular (CV) death 30 days after PCI. Methods: Univariate analysis of base-
line, angiographic, procedural data points were associated with the endpoints of MI or
(CV) death at 30 days as determined by the clinical endpoints committee for the
REPLACE - 2 trial. Variables with statistical significance (p<0.05) were then tested in a
multivariate logistic regression model as predictors for the same endpoints. From this
model four of the statistically significant variables were then assigned a value of 1 if
present in each patient. These variables included LVEF <35%, > 2 lesions attempted,
AHA/ACC lesion score B2 or C, and any stent deployment. Each patient was then
assigned a cumulative score of 0 to 4 based on the presence of these four variables.
Patient groups defined by their cumulative score were then correlated with the risk of MI
and CV death at 30 days. This same risk score was then applied to the TARGET data
using slightly modified variables to account for differences in acquired data points.
Results: There was a near linear correlation between cumulative risk score and the end-
points of MI and CV death. For the REPLACE – 2 data risk score stratification of
0,1,2,3,and 4 correlated with endpoint rates of 2.07, 4.14, 6.89, 11.38, and 9.80%
respectively (p<0.001). Risk score stratification of the TARGET data yielded similar
results with cumulative risk score groups 0,1,2,3,and 4 associated with endpoint rates of
1.10, 4.01, 7.80, 10.61, and 16.67 % respectively (p<0.001). The C statistic for the risk
score in REPLACE2 is 0.622, and is 0.613 when tested in TARGET. Conclusions: A sim-
ple cumulative risk using four easily accessible variables can help predict the probability
of MI and cardiovascular death at 30 days.
1043-66 Procedural Predictors of Creatine Kinase-MB Elevations 
in the REPLACE-2 Study
Kirk Gavlick, James C. Blankenship, Neal S. Kleiman, John A. Bittl, Frederick Feit, Eric J. 
Topol, A. Michael Lincoff, Geisinger Medical Center, Danville, PA, Cleveland Clinic 
Foundation, Cleveland, OH
BACKGROUND: Angiographic complications (AC) of percutaneous coronary interven-
tion (PCI) predict creatine kinase – MB (CK-MB) elevation after PCI and are decreased
by intravenous 2b/3a inhibitors. We analyzed data from REPLACE-2 to determine if simi-
lar results were obtained with bivalirudin.
METHODS: In REPLACE-2, 6010 patients were randomized to bivalirudin versus hep-
arin plus eptifibatide or abciximab during PCI. AC were recorded by operators at the time
of PCI. CK-MB was measured at 8 hour intervals after PCI.
RESULTS: Angiographic complications occurred in 10.3% of patients, including 11% in
bivalirudin-treated patients and 9.5% in heparin-2b/3a patients (p = 0.053). All 13 catego-
ries of AC occurred with similar frequency in both groups. These included decreased flow
during PCI, severe dissection , new thrombus, distal embolization, unplanned stenting,
side branch occlusion, abrupt closure, and prolonged ischemia of any cause (p > 0.25 for
each).
CK-MB > 3 x normal occurred in 7.5% of patients and was similar for both treatment
arms. CK-MB > 3 x normal occurred with increased frequency in patients with AC com-
pared to those without (22.9% vs 3.7%, RR = 4.0, p < 0.001). Of 13 AC types, 11 were
predictive of CK-MB > 3 x normal including distal embolization (relative risk (RR) 14, p <
0.001), side branch occlusion (RR = 13, p < 0.01), any cause of prolonged ischemia (RR
= 13, p < 0.01), and transient slow flow (RR 8, p < 0.01). However, of 388 patients with
CK-MB > 3 x normal, 265 (68%) had angiographiclly uncomplicated, successful proce-
dures.
CONCLUSIONS: Bivalirudin is as effective as heparin with 2b/3a inhibitors in preventing
AC during PCI. The occurrence of AC entails a four-fold risk of CK-MB > 3 times normal
after PCI. However, CK-MB > 3 x normal occurs in 5.7% of patients whose PCI is angio-
graphically uncomplicated, and 2/3 of all CK-MB elevations occur after uncomplicated
PCI. Routine CK-MB enzyme monitoring after PCI is still necessary, since selective CK-
MB enzyme monitoring only after AC occur would miss many CK-MB elevations.
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1044-51 PeriStent Restenosis Following Drug-Eluting Stents: 
Influence of Contributing Factors
David O. Williams, David Snead, Jeffrey J. Popma, Rhode Island Hospital, Providence, 
RI
Background: In the SIRIUS trial the effectiveness of sirolimus-eluting stents was dimin-
ished by re-stenosis at stent margins, particularly at the proximal site.
Methods: To better understand this finding we sought to identify factors associated with
peri-stent restenosis using the clinical, angiographic and intravascular ultrasound (IVUS)
databases of the SIRIUS trial. Patients within the SIRIUS trial with angiographic and
IVUS baseline and follow-up evaluations formed the study cohort.
Results: There was no significant relationship between stent to lesion ratio (SLR) and
binary peri-stent restenosis rate by univariate analysis. Regression relationships were
developed comparing SLR to proximal margin late loss (mm), distal margin late loss
(mm) by quantitative angiography and by IVUS determined follow-up proximal and distal
margin plaque volumes (mm3) and follow-up proximal and distal margin minimal lumen
diameters (mm). None of these analyses revealed a significant relationship between SLR
and any of the outcome variables for either sirolimus-treated or bare stent patients.
Univariate analysis of sirolimus treated patients demonstrated a significant (p<0.05)
association between proximal/distal restenosis rate (peri-stent restenosis) at 8 months
and post-procedure in-stent minimal lumen diameter (OR 0.23, p<0.002), pre-procedure
reference vessel diameter (OR 0.32, p<0.004), post-procedure reference vessel diameter
(OR 0.32, p<0.006) history of diabetes (OR 2.3, p<0.01) and cigarette smoking within the
past year (OR 2.1, p<0.03). Factors associated with proximal/distal restenosis by multi-
variate modeling included post-procedure minimal lumen diameter (OR 0.23, p<0.002),
cigarette smoking during the past year (OR 2.3, p<0.02) and history of diabetes (OR 2.1,
p<0.03).
Conclusions: Peri-stent restenosis was related to smaller vessel diameter and the his-
tory of diabetes or recent cigarette smoking. We did not detect a relationship between
SLR and peri-stent restenosis. These findings could influence the technique for utilizing
drug-eluting stents. Caution is advised, however, in interpreting these results given the
low event rate of peri-stent restenosis.
